Dasatinib leukaemia drug action

Videonummer 11930057
Dasatinib leukaemia drug binding to its target, the enzyme Bcr-Abl tyrosine kinase. This enzyme is produced by a genetic mutation, the swapping of parts of two chromosomes, leading to the formation of the oncogene (cancer-causing gene) Bcr-Abl, which produces a constantly-active version of normal Abl tyrosine kinase. This causes chronic myelogenous leukaemia (CML), a cancer of white blood cells. The drug Sprycel (Dasatinib) works by binding to the active site of the Bcr-Abl enzyme, producing a change in shape that prevents the enzyme from functioning. This causes the death of cancerous cells expressing the enzyme. Sprycel is marketed by Bristol-Myers Squibb.
Lizenzart: Lizenzpflichtig
Credit: Science Photo Library / Andrade, Ramon / 3dciencia
Modell-Rechte: nicht erforderlich
Eigentums-Rechte: nicht erforderlich
Länge: 10 Sekunden
Seitenverhältnis: 16:9
Restrictions: -

Preise für dieses Video ab 100 €

Werblich (Einzelne Webseiten etc.) ab 100 €
Redaktionell (Einzelne Webseiten etc.) ab 175 €
Medien (TV Film, Serie, TV Doku etc.) ab 230 €

Keywords

;